改良格拉斯哥预后评分(mGPS)可指导疾病进展后免疫治疗的决策
该研究对IMmotion151(肾细胞癌)、OAK(非小细胞肺癌)和IMvigor211(尿路上皮癌)三项随机3期试验的免疫治疗组进行事后分析,评估进展时改良格拉斯哥预后评分(mGPS)对进展后总生存(PPOS)的预后价值及对疾病进展后治疗(TBP)获益的预测作用。结果显示,进展时mGPS高危与显著缩短的PPOS相关,且仅低危组患者从继续阿替利珠单抗TBP中获益。
要点
- 进展时mGPS高危与肾细胞癌、尿路上皮癌和非小细胞肺癌患者显著更短的进展后总生存相关。
- 仅进展时mGPS低危患者从继续阿替利珠单抗治疗中获益,中/高危患者未见获益。
- 放射学进展时评估mGPS有助于识别可能从继续阿替利珠单抗治疗中获益的患者。
核心结论
- 研究结果表明,放射学进展时测定的mGPS可识别预后较好、可能从继续阿替利珠单抗治疗中获益的患者,有助于临床实践中筛选适合TBP的患者。
研究设计与样本
- 对IMmotion151(肾细胞癌)、OAK(非小细胞肺癌)和IMvigor211(尿路上皮癌)三项随机3期试验免疫治疗组进行事后分析。
- 主要结局为首次研究者评估的疾病进展(PD)后的进展后总生存(PPOS),按mGPS风险组分析。
- mGPS基于C反应蛋白(CRP)和白蛋白将患者分为三个风险组。
主要发现
- 进展时mGPS高危与低危相比,肾细胞癌死亡HR为18.3(95%CI 6.71-50.0,p<0.001),尿路上皮癌HR为4.16(95%CI 2.58-6.69,p<0.001),非小细胞肺癌HR为2.53(95%CI 1.70-3.77,p<0.001)。
- 仅进展时mGPS低危组患者从继续免疫检查点抑制剂治疗(TBP)对比换用后线治疗中获益:肾细胞癌HR为0.18(95%CI 0.06-0.55,p=0.002);尿路上皮癌HR为0.59(95%CI 0.34-1.00,p=0.052);非小细胞肺癌HR为0.62(95%CI 0.41-0.92,p=0.018),均与进展时mGPS中/高危组相比。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treatment beyond progression (TBP) is common in patients treated with immune-checkpoint inhibitors (ICI), however, there is no biomarker to select patients that are more likely to derive benefit from TBP. Here, we investigated the potential of the modified Glasgow Prognostic Score (mGPS) as a predictive biomarker to select patients for TBP. METHODS: We performed a post-hoc analysis of the immunotherapy arms in the randomized phase 3 trials IMmotion151 (renal cell carcinoma), OAK (non-small cell lung cancer) and IMvigor211 (urothelial cancer). The main outcome was post-progression overall survival (PPOS) after the first investigator-assessed disease progression (PD), in mGPS risk groups. The mGPS classifies patients into three risk groups based on C-reactive protein (CRP) and albumin. RESULTS: We found a strong prognostic value for the mGPS when assessed at the time of PD (PD-mGPS) in all three trials. High-risk PD-mGPS was associated with significantly shorter PPOS compared to low-risk PD-mGPS (HR for death 18.3 (95 % CI 6.71-50.0, p < 0.001)) for RCC, UC: HR 4.16 (95 % CI 2.58-6.69, p < 0.001) and NSCLC HR 2.53 (95 % CI 1.70-3.77, p < 0.001). Importantly, patients within all three trials only derived benefit from ICI-TBP compared to switch to further-line treatment in the PD-mGPS low-risk group (RCC: HR 0.18 (95 % CI 0.06-0.55, p = 0.002); UC: HR 0.59 (95 % CI 0.34-1.00, p = 0.052); NSCLC: 0.62 (0.41-0.92, p = 0.018) compared to PD-mGPS intermediate/ high risk). CONCLUSIONS: These findings suggest that the mGPS measured at the time of radiologic PD can identify patients with a better prognosis who may benefit from continued atezolizumab therapy, aiding in the selection for TBP in clinical practice.
引用
- Saal J, Eckstein M, Ritter M, et al. The modified Glasgow Prognostic Score (mGPS) can guide decisions for immunotherapy treatment beyond progression. Eur J Cancer. 2024. PMID: 39662097. doi:10.1016/j.ejca.2024.115163
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。